All Comments by
- Michael G. Agadjanyan on Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
- David Holtzman on AD Immunotherapy: Toward Prevention, DNA-based Vaccines?
- Rachelle Doody on Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
- Akihiko Nunomura on Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice.
- Russell Swerdlow on Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats.
- Stephen Staten on Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance.
- Paula Moreira on Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats.
- Jungsu Kim on BACE Inhibitors Hitch Ride into Endosomes via Membrane Anchor
- Gjumrakch Aliev on A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta.
- Barbara Calabrese on Plaque Microglia—Mobile But Limited
- Jordan Tang on BACE Inhibitors Hitch Ride into Endosomes via Membrane Anchor
- Benjamin Wolozin on Trial Troika—Immunotherapy Interrupted, Lipitor Lags, Dimebon Delivers
- Michael Parker on Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation.
- J. Lucy Boyd on HAI Chicago: PIB in Healthy People
- Lary Walker on Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid.